Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 20/20 | 0.75 |
| ▸ | BACE2 | Q9Y5Z0 | 4/20 | 0.57 |
| ▸ | APP | P05067 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Formic Acid SCHEMBL12478548 | 1.00 | BACE1 (0.75) | BACE1BACE2APP | |
| SCHEMBL12697025 | 0.97 | BACE1 (0.79) | BACE1BACE2APP | |
| Formic Acid SCHEMBL15467511 | 0.90 | BACE1 (0.80) | BACE1BACE2APP | |
| Formic Acid SCHEMBL15467510 | 0.90 | BACE1 (0.80) | BACE1BACE2APP | |
| Formic Acid SCHEMBL2593148 | 0.89 | BACE1 (0.81) | BACE1BACE2APP | |
| Formic Acid SCHEMBL15467867 | 0.89 | BACE1 (0.81) | BACE1BACE2APP | |
| Formic Acid SCHEMBL15467548 | 0.89 | BACE1 (0.80) | BACE1BACE2APP | |
| Formic Acid SCHEMBL2594334 | 0.89 | BACE1 (0.80) | BACE1BACE2APP | |
| Formic Acid SCHEMBL15467656 | 0.88 | BACE1 (0.73) | BACE1BACE2 | |
| Formic Acid SCHEMBL15467549 | 0.88 | BACE1 (0.75) | BACE1BACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140323469-A1 | 1,4 OXAZEPINES AS BACE1 AND/OR BACE2 INHIBITORS | SIENA BIOTECH S.P.A. (IT) | 2014-10-30 | — | — | US | claimed |
| EP-2675796-A1 | 1,4-OXAZEPINES AS BACE1 AND/OR BACE2 INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-12-25 | — | — | EP | claimed |
| US-20130040936-A1 | 1,4-OXAZEPINES AS BACE1 AND/OR BACE2 INHIBITORS | HOFFMANN-LA ROCHE INC. | 2013-02-14 | — | — | US | claimed |
| WO-2012110459-A1 | 1,4-OXAZEPINES AS BACE1 AND/OR BACE2 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-08-23 | — | — | WO | claimed |
| US-20140323469-A1 | 1,4 OXAZEPINES AS BACE1 AND/OR BACE2 INHIBITORS | SIENA BIOTECH S.P.A. (IT) | 2014-10-30 | — | — | US | disclosed |
| US-8815841-B2 | 1,4-Oxazepines as BACE1 and/or BACE2 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2014-08-26 | — | — | US | disclosed |
| US-20130040936-A1 | 1,4-OXAZEPINES AS BACE1 AND/OR BACE2 INHIBITORS | HOFFMANN-LA ROCHE INC. | 2013-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140323469-A1 | 1,4 OXAZEPINES AS BACE1 AND/OR BACE2 INHIBITORS | BACE1, BACE2, PSEN2 | BACE1 1/4885BACE2 2/4885APP 5/4885 |
| US-20130040936-A1 | 1,4-OXAZEPINES AS BACE1 AND/OR BACE2 INHIBITORS | BACE1, BACE2, PSEN2 | BACE1 1/4885BACE2 2/4885APP 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.